97 related articles for article (PubMed ID: 8758438)
1. [Anti-tumor effects of bispecific monoclonal antibody targeted human monocytes-macrophages on hepatoma cells].
Wang Q; Chen Z; Wang W
Zhonghua Yi Xue Za Zhi; 1996 Feb; 76(2):96-9. PubMed ID: 8758438
[TBL] [Abstract][Full Text] [Related]
2. Bispecific F (ab')2 monomer prepared with anti-CD3 and anti-tumor monoclonal antibodies is most potent in induction of cytolysis of human T cells.
Nitta T; Yagita H; Azuma T; Sato K; Okumura K
Eur J Immunol; 1989 Aug; 19(8):1437-41. PubMed ID: 2528460
[TBL] [Abstract][Full Text] [Related]
3. [Bi-specific F(ab')2 enhances cytolytic activities of LAK cells against human small cell lung cancer (SCLC)].
Azuma A; Niitani H
Nihon Kyobu Shikkan Gakkai Zasshi; 1991 Sep; 29(9):1132-7. PubMed ID: 1661346
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a novel bispecific antibody that mediates Fcgamma receptor type I-dependent killing of tumor-associated glycoprotein-72-expressing tumor cells.
Russoniello C; Somasundaram C; Schlom J; Deo YM; Keler T
Clin Cancer Res; 1998 Sep; 4(9):2237-43. PubMed ID: 9748144
[TBL] [Abstract][Full Text] [Related]
5. [Preparation and in vitro killing effect of adriamycin-loaded immunonanosphere against hepatoma led by F (ab')2 Fragment of monoclonal antibodies].
Li Y; Cai M; Wang Z; Liu X; Liang Z
Hua Xi Yi Ke Da Xue Xue Bao; 2002 Jan; 33(1):8-11, 14. PubMed ID: 12599415
[TBL] [Abstract][Full Text] [Related]
6. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
[TBL] [Abstract][Full Text] [Related]
7. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
Gautherot E; Le Doussal JM; Bouhou J; Manetti C; Martin M; Rouvier E; Barbet J
J Nucl Med; 1998 Nov; 39(11):1937-43. PubMed ID: 9829586
[TBL] [Abstract][Full Text] [Related]
8. [Biological distribution of 131I-HAb18F(ab')2 in patients with hepatocellular carcinoma].
Lu W; Li X; Wang C; Liu W; Jiao H; Mo T; Chen Z
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2003 Dec; 20(4):689-91. PubMed ID: 14716878
[TBL] [Abstract][Full Text] [Related]
9. Cross-reaction of a rat-anti-mouse phagocyte-specific monoclonal antibody (anti-Mac-1) with human monocytes and natural killer cells.
Ault KA; Springer TA
J Immunol; 1981 Jan; 126(1):359-64. PubMed ID: 7451976
[TBL] [Abstract][Full Text] [Related]
10. Development of a trispecific antibody conjugate that directs two distinct tumor-associated antigens to CD64 on myeloid effector cells.
Somasundaram C; Sundarapandiyan K; Keler T; Deo YM; Graziano RF
Hum Antibodies; 1999; 9(1):47-54. PubMed ID: 10331185
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a new monoclonal anti-Fc gamma RII antibody, AT10, and its incorporation into a bispecific F(ab')2 derivative for recruitment of cytotoxic effectors.
Greenman J; Tutt AL; George AJ; Pulford KA; Stevenson GT; Glennie MJ
Mol Immunol; 1991 Nov; 28(11):1243-54. PubMed ID: 1835758
[TBL] [Abstract][Full Text] [Related]
12. CD3 directed bispecific antibodies induce increased lymphocyte-endothelial cell interactions in vitro.
Molema G; Tervaert JW; Kroesen BJ; Helfrich W; Meijer DK; de Leij LF
Br J Cancer; 2000 Jan; 82(2):472-9. PubMed ID: 10646907
[TBL] [Abstract][Full Text] [Related]
13. Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood.
Deo YM; Sundarapandiyan K; Keler T; Wallace PK; Graziano RF
J Immunol; 1998 Feb; 160(4):1677-86. PubMed ID: 9469424
[TBL] [Abstract][Full Text] [Related]
14. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.
Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF
Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826
[TBL] [Abstract][Full Text] [Related]
15. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.
Keler T; Graziano RF; Mandal A; Wallace PK; Fisher J; Guyre PM; Fanger MW; Deo YM
Cancer Res; 1997 Sep; 57(18):4008-14. PubMed ID: 9307286
[TBL] [Abstract][Full Text] [Related]
16. [Internalization of antibody-targeted immunonanoparticles into human hepatoma cells and its reversal effect on MDR].
Liu X; Wang X; Wei D; Cai M; Li G
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jul; 34(3):431-4. PubMed ID: 12910681
[TBL] [Abstract][Full Text] [Related]
17. Tumor therapy with bispecific antibody: the targeting and triggering steps can be separated employing a CD2-based strategy.
Wild MK; Strittmatter W; Matzku S; Schraven B; Meuer SC
J Immunol; 1999 Aug; 163(4):2064-72. PubMed ID: 10438945
[TBL] [Abstract][Full Text] [Related]
18. Rapid and potent induction of cell death and loss of NK cell cytotoxicity against oral tumors by F(ab')2 fragment of anti-CD16 antibody.
Jewett A; Teruel A; Romero M; Head C; Cacalano N
Cancer Immunol Immunother; 2008 Jul; 57(7):1053-66. PubMed ID: 18188563
[TBL] [Abstract][Full Text] [Related]
19. Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody.
Bartlett JS; Kleinschmidt J; Boucher RC; Samulski RJ
Nat Biotechnol; 1999 Feb; 17(2):181-6. PubMed ID: 10052356
[TBL] [Abstract][Full Text] [Related]
20. Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2) constructs in a breast carcinoma xenograft model.
Tahtis K; Lee FT; Smyth FE; Power BE; Renner C; Brechbiel MW; Old LJ; Hudson PJ; Scott AM
Clin Cancer Res; 2001 Apr; 7(4):1061-72. PubMed ID: 11309358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
